Market capitalization | $2.88b |
Enterprise Value | $2.26b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 62.87 |
P/S ratio (TTM) P/S ratio | 80.16 |
P/B ratio (TTM) P/B ratio | 4.09 |
Revenue growth (TTM) Revenue growth | -21.33% |
Revenue (TTM) Revenue | $35.93m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
18 Analysts have issued a Merus N.V. forecast:
18 Analysts have issued a Merus N.V. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 36 36 |
21%
21%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -228 -228 |
42%
42%
|
EBIT (Operating Income) EBIT | -231 -231 |
42%
42%
|
Net Profit | -245 -245 |
38%
38%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
Head office | Netherlands |
CEO | Bill Lundberg |
Employees | 229 |
Founded | 2003 |
Website | www.merus.nl |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.